Amyloidosis from the patient perspective: the French daily impact of amyloidosis study
Thibaud Damy(Amyloidosis Foundation), Sophie Georgin‐Lavialle(Inserm), Gilles Grateau(Sorbonne Université), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Agnès Farrugia, Yves Ghiron(Inserm), C. Taïeb(Huashan Hospital), Céline Labeyrie(Bicêtre Hospital), Frank Bridoux(Université de Poitiers), David Adams(Mount Sinai Health System), F. Pelcot
Cited by 46
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k